| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell | 6 | 2023 | 103 | 3.400 |
Why?
|
| Hodgkin Disease | 12 | 2024 | 177 | 3.240 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 12 | 2023 | 151 | 3.060 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 5 | 2023 | 27 | 2.150 |
Why?
|
| Biomarkers, Tumor | 8 | 2019 | 1464 | 1.300 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2023 | 107 | 1.170 |
Why?
|
| Bone Marrow | 4 | 2022 | 435 | 1.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 136 | 1.110 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2017 | 21 | 1.070 |
Why?
|
| Mediastinal Neoplasms | 2 | 2022 | 46 | 1.020 |
Why?
|
| 5-Methylcytosine | 2 | 2022 | 112 | 0.950 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2023 | 189 | 0.890 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 20 | 0.870 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2022 | 29 | 0.860 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2019 | 50 | 0.840 |
Why?
|
| Lymphoma, T-Cell | 1 | 2022 | 48 | 0.830 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2021 | 35 | 0.810 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2020 | 5 | 0.780 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2017 | 173 | 0.750 |
Why?
|
| STAT6 Transcription Factor | 1 | 2019 | 28 | 0.730 |
Why?
|
| Leukemia | 1 | 2022 | 320 | 0.720 |
Why?
|
| Bone Marrow Cells | 3 | 2019 | 253 | 0.690 |
Why?
|
| Humans | 66 | 2024 | 86645 | 0.680 |
Why?
|
| Reed-Sternberg Cells | 3 | 2024 | 4 | 0.630 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 1195 | 0.610 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 261 | 0.610 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 107 | 0.580 |
Why?
|
| Erythrocyte Aggregation | 1 | 2016 | 4 | 0.560 |
Why?
|
| Infectious Mononucleosis | 1 | 2016 | 6 | 0.560 |
Why?
|
| Histiocytosis, Sinus | 2 | 2019 | 14 | 0.550 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 1565 | 0.550 |
Why?
|
| Adenocarcinoma | 3 | 2008 | 1169 | 0.550 |
Why?
|
| Lymphocytes | 3 | 2023 | 464 | 0.550 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2019 | 372 | 0.520 |
Why?
|
| Piperidines | 4 | 2021 | 181 | 0.490 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 456 | 0.480 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 7 | 0.480 |
Why?
|
| CD11c Antigen | 1 | 2013 | 11 | 0.480 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2013 | 27 | 0.470 |
Why?
|
| Cytoplasmic Granules | 1 | 2013 | 94 | 0.460 |
Why?
|
| Herpesvirus 8, Human | 1 | 2013 | 11 | 0.460 |
Why?
|
| Sarcoma, Kaposi | 1 | 2013 | 19 | 0.460 |
Why?
|
| Castleman Disease | 1 | 2013 | 13 | 0.460 |
Why?
|
| Antigens, CD | 2 | 2013 | 458 | 0.460 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2013 | 17 | 0.460 |
Why?
|
| Middle Aged | 27 | 2021 | 25028 | 0.450 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 49 | 0.450 |
Why?
|
| Prostatic Neoplasms | 4 | 2008 | 1721 | 0.450 |
Why?
|
| Down-Regulation | 2 | 2022 | 504 | 0.430 |
Why?
|
| Immunohistochemistry | 9 | 2022 | 1753 | 0.430 |
Why?
|
| B-Lymphocytes | 5 | 2023 | 724 | 0.430 |
Why?
|
| Monocytes | 1 | 2013 | 214 | 0.430 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2011 | 4 | 0.420 |
Why?
|
| Male | 33 | 2023 | 40967 | 0.410 |
Why?
|
| Integrin alpha Chains | 1 | 2011 | 15 | 0.410 |
Why?
|
| Lewis X Antigen | 1 | 2011 | 9 | 0.400 |
Why?
|
| Fucosyltransferases | 1 | 2011 | 8 | 0.400 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2023 | 159 | 0.400 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2011 | 16 | 0.400 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2011 | 186 | 0.400 |
Why?
|
| Sclerosis | 1 | 2010 | 28 | 0.390 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2010 | 22 | 0.380 |
Why?
|
| Dura Mater | 1 | 2010 | 44 | 0.380 |
Why?
|
| Female | 30 | 2021 | 44534 | 0.380 |
Why?
|
| Prognosis | 9 | 2023 | 3680 | 0.380 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 1 | 2010 | 2 | 0.380 |
Why?
|
| Aged | 23 | 2021 | 18415 | 0.370 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 61 | 0.370 |
Why?
|
| Histiocytic Sarcoma | 1 | 2010 | 8 | 0.370 |
Why?
|
| Image Cytometry | 2 | 2007 | 12 | 0.370 |
Why?
|
| Neoplasms | 2 | 2020 | 2898 | 0.350 |
Why?
|
| Flow Cytometry | 5 | 2024 | 679 | 0.350 |
Why?
|
| Adult | 22 | 2024 | 25648 | 0.350 |
Why?
|
| Pyrimidines | 3 | 2018 | 370 | 0.340 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 381 | 0.330 |
Why?
|
| DNA, Neoplasm | 4 | 2013 | 265 | 0.330 |
Why?
|
| Immunophenotyping | 4 | 2019 | 211 | 0.330 |
Why?
|
| Aneuploidy | 2 | 2007 | 55 | 0.330 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2023 | 132 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2023 | 592 | 0.320 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 532 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1313 | 0.310 |
Why?
|
| Lymph Nodes | 3 | 2020 | 533 | 0.300 |
Why?
|
| Ploidies | 1 | 2006 | 40 | 0.290 |
Why?
|
| Pyrazoles | 2 | 2018 | 153 | 0.280 |
Why?
|
| Phenotype | 2 | 2023 | 2378 | 0.280 |
Why?
|
| Pathology, Clinical | 1 | 2006 | 33 | 0.280 |
Why?
|
| Logistic Models | 2 | 2007 | 1187 | 0.280 |
Why?
|
| Neoplasm Staging | 6 | 2016 | 1939 | 0.280 |
Why?
|
| Flavonoids | 1 | 2006 | 85 | 0.270 |
Why?
|
| Adenine | 3 | 2021 | 85 | 0.270 |
Why?
|
| Plasma Cells | 2 | 2019 | 80 | 0.270 |
Why?
|
| Observer Variation | 2 | 2007 | 602 | 0.260 |
Why?
|
| Statistics as Topic | 1 | 2006 | 238 | 0.260 |
Why?
|
| Adolescent | 9 | 2024 | 8982 | 0.250 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 2360 | 0.250 |
Why?
|
| Biopsy | 2 | 2019 | 1163 | 0.250 |
Why?
|
| Biomarkers | 3 | 2023 | 1718 | 0.250 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 104 | 0.250 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2023 | 5 | 0.230 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 388 | 0.230 |
Why?
|
| In Situ Hybridization | 4 | 2013 | 307 | 0.230 |
Why?
|
| Dermatitis | 1 | 2023 | 32 | 0.230 |
Why?
|
| Exanthema | 1 | 2023 | 36 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 878 | 0.220 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 53 | 0.220 |
Why?
|
| Young Adult | 10 | 2024 | 5976 | 0.220 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 689 | 0.210 |
Why?
|
| Apoptosis | 2 | 2023 | 1683 | 0.210 |
Why?
|
| Cyclin D1 | 2 | 2016 | 83 | 0.210 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 1673 | 0.210 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2022 | 427 | 0.210 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 162 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 567 | 0.200 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 206 | 0.200 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 250 | 0.200 |
Why?
|
| Cell Proliferation | 2 | 2023 | 1578 | 0.200 |
Why?
|
| Cell Nucleus | 3 | 2008 | 579 | 0.200 |
Why?
|
| Cell Lineage | 1 | 2022 | 273 | 0.200 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6509 | 0.200 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 241 | 0.200 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 76 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 365 | 0.190 |
Why?
|
| Spleen | 2 | 2013 | 430 | 0.190 |
Why?
|
| Chromothripsis | 1 | 2020 | 5 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 2438 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2020 | 24 | 0.190 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2020 | 14 | 0.180 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2019 | 4 | 0.180 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 1686 | 0.180 |
Why?
|
| Mastitis | 1 | 2019 | 5 | 0.180 |
Why?
|
| Sezary Syndrome | 1 | 2019 | 8 | 0.180 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 12 | 0.180 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2009 | 383 | 0.180 |
Why?
|
| Genomic Instability | 1 | 2020 | 79 | 0.180 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 235 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 375 | 0.180 |
Why?
|
| Mycosis Fungoides | 1 | 2019 | 23 | 0.180 |
Why?
|
| Ki-1 Antigen | 1 | 2019 | 17 | 0.180 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2019 | 49 | 0.170 |
Why?
|
| Breast Diseases | 1 | 2019 | 97 | 0.170 |
Why?
|
| Thymus Neoplasms | 1 | 2019 | 41 | 0.170 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 48 | 0.170 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 17 | 0.170 |
Why?
|
| Sulfonamides | 1 | 2021 | 300 | 0.170 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 79 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 71 | 0.160 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 46 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 479 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 120 | 0.160 |
Why?
|
| Breast | 1 | 2019 | 288 | 0.160 |
Why?
|
| Mutation | 4 | 2022 | 3968 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 425 | 0.150 |
Why?
|
| Muscle, Smooth | 2 | 2009 | 354 | 0.140 |
Why?
|
| CD5 Antigens | 1 | 2016 | 14 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2009 | 164 | 0.140 |
Why?
|
| Coombs Test | 1 | 2016 | 8 | 0.140 |
Why?
|
| Burkitt Lymphoma | 1 | 2015 | 31 | 0.130 |
Why?
|
| Melanoma | 1 | 2020 | 459 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 329 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 348 | 0.130 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2023 | 35 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 302 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 546 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 272 | 0.120 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1384 | 0.120 |
Why?
|
| Chediak-Higashi Syndrome | 1 | 2013 | 1 | 0.120 |
Why?
|
| Leukocytosis | 1 | 2013 | 16 | 0.120 |
Why?
|
| Blood Cell Count | 1 | 2013 | 79 | 0.120 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 61 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2013 | 2767 | 0.120 |
Why?
|
| Data Mining | 1 | 2013 | 42 | 0.120 |
Why?
|
| Survival Rate | 2 | 2019 | 1863 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 927 | 0.110 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 9 | 0.110 |
Why?
|
| Laser Capture Microdissection | 1 | 2013 | 20 | 0.110 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 2426 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 303 | 0.110 |
Why?
|
| Viral Load | 1 | 2013 | 148 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2013 | 265 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 879 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2010 | 100 | 0.110 |
Why?
|
| Gene Rearrangement | 1 | 2013 | 170 | 0.100 |
Why?
|
| Pseudolymphoma | 1 | 2011 | 9 | 0.100 |
Why?
|
| Cell Separation | 1 | 2011 | 196 | 0.100 |
Why?
|
| Mucous Membrane | 2 | 2009 | 83 | 0.100 |
Why?
|
| Urothelium | 2 | 2009 | 70 | 0.100 |
Why?
|
| Clone Cells | 1 | 2010 | 213 | 0.090 |
Why?
|
| Oral Ulcer | 1 | 2010 | 3 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 1 | 2011 | 114 | 0.090 |
Why?
|
| Skin Diseases, Infectious | 1 | 2010 | 13 | 0.090 |
Why?
|
| Recurrence | 3 | 2023 | 1139 | 0.090 |
Why?
|
| Rituximab | 2 | 2023 | 116 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 814 | 0.090 |
Why?
|
| Piperazines | 1 | 2012 | 272 | 0.090 |
Why?
|
| Skin Ulcer | 1 | 2010 | 25 | 0.090 |
Why?
|
| fas Receptor | 1 | 2010 | 75 | 0.090 |
Why?
|
| Family Health | 1 | 2010 | 162 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2010 | 293 | 0.090 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 387 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 286 | 0.090 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 418 | 0.080 |
Why?
|
| Myoepithelioma | 1 | 2008 | 11 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 276 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 146 | 0.080 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2008 | 28 | 0.080 |
Why?
|
| Parotid Neoplasms | 1 | 2008 | 17 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1805 | 0.080 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2007 | 6 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2009 | 132 | 0.080 |
Why?
|
| Karyotype | 2 | 2019 | 33 | 0.080 |
Why?
|
| Discriminant Analysis | 1 | 2007 | 66 | 0.080 |
Why?
|
| Sarcoma, Ewing | 1 | 2007 | 42 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2009 | 223 | 0.080 |
Why?
|
| Mice | 4 | 2023 | 11352 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2010 | 337 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 329 | 0.080 |
Why?
|
| Sarcoma, Synovial | 1 | 2007 | 21 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 596 | 0.070 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2007 | 27 | 0.070 |
Why?
|
| Histological Techniques | 1 | 2006 | 35 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2007 | 68 | 0.070 |
Why?
|
| Photometry | 1 | 2006 | 14 | 0.070 |
Why?
|
| Antibodies | 1 | 2009 | 350 | 0.070 |
Why?
|
| Testicular Neoplasms | 1 | 2007 | 105 | 0.070 |
Why?
|
| Cytogenetic Analysis | 1 | 2006 | 71 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 36 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2023 | 3241 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 46 | 0.070 |
Why?
|
| Papillomaviridae | 1 | 2007 | 153 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2007 | 127 | 0.070 |
Why?
|
| Retinoblastoma Protein | 1 | 2006 | 66 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2006 | 159 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3640 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2007 | 246 | 0.070 |
Why?
|
| Genetic Markers | 1 | 2006 | 476 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 353 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2019 | 7993 | 0.060 |
Why?
|
| Cytological Techniques | 1 | 2005 | 30 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 977 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 589 | 0.060 |
Why?
|
| India | 1 | 2005 | 120 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 239 | 0.060 |
Why?
|
| ROC Curve | 1 | 2006 | 752 | 0.060 |
Why?
|
| Carcinoma | 1 | 2007 | 436 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2007 | 403 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2007 | 575 | 0.060 |
Why?
|
| Vincristine | 1 | 2023 | 111 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2023 | 52 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2007 | 645 | 0.060 |
Why?
|
| Prednisone | 1 | 2023 | 258 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2006 | 471 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 299 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2023 | 295 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 4213 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2023 | 135 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 134 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2023 | 179 | 0.050 |
Why?
|
| Animals | 4 | 2023 | 26582 | 0.050 |
Why?
|
| Child | 1 | 2013 | 6928 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 8491 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 295 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 298 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 1204 | 0.050 |
Why?
|
| Emperipolesis | 1 | 2019 | 1 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2021 | 113 | 0.050 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2019 | 15 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2020 | 58 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2020 | 110 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2007 | 2262 | 0.050 |
Why?
|
| Erythroid Cells | 1 | 2019 | 14 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 1531 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 2019 | 36 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2019 | 50 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2021 | 420 | 0.040 |
Why?
|
| United States | 2 | 2024 | 6674 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 117 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 98 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2020 | 207 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 234 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1041 | 0.040 |
Why?
|
| Tretinoin | 1 | 2019 | 126 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 203 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 2020 | 164 | 0.040 |
Why?
|
| Benzodioxoles | 1 | 2018 | 16 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2019 | 165 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 149 | 0.040 |
Why?
|
| Purines | 1 | 2018 | 91 | 0.040 |
Why?
|
| Histiocytes | 1 | 2017 | 22 | 0.040 |
Why?
|
| World Health Organization | 2 | 2007 | 103 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2379 | 0.040 |
Why?
|
| Time Factors | 1 | 2006 | 5210 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 458 | 0.040 |
Why?
|
| src Homology Domains | 1 | 2016 | 44 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 3047 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1204 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2019 | 444 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 552 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 526 | 0.030 |
Why?
|
| Genomics | 1 | 2020 | 720 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1197 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 2013 | 129 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 456 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1538 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2012 | 23 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2012 | 126 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2011 | 20 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 1056 | 0.020 |
Why?
|
| Developed Countries | 1 | 2011 | 24 | 0.020 |
Why?
|
| Benzamides | 1 | 2012 | 229 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2010 | 20 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 53 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 67 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 2010 | 111 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 129 | 0.020 |
Why?
|
| Fractures, Compression | 1 | 2007 | 17 | 0.020 |
Why?
|
| Bone Screws | 1 | 2007 | 44 | 0.020 |
Why?
|
| Pathology | 1 | 2007 | 30 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 281 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 148 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2007 | 44 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2007 | 85 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2007 | 75 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 124 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 148 | 0.020 |
Why?
|
| Aging | 1 | 2011 | 691 | 0.020 |
Why?
|
| Urology | 1 | 2007 | 110 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1851 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2007 | 572 | 0.010 |
Why?
|
| Prostate | 1 | 2006 | 378 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1991 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1036 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3362 | 0.010 |
Why?
|